Glucagon-like peptide 1 receptor agonist (GLP-1 RA): Long-term effect on kidney function in patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) : Long-term effect on kidney function in patients with type 2 diabetes. / Von Scholten, Bernt Johan; Hansen, Tine Willum; Goetze, Jens Peter; Persson, Frederik; Rossing, Peter.

In: Journal of Diabetes and its Complications, Vol. 29, No. 5, 01.07.2015, p. 670-674.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Von Scholten, BJ, Hansen, TW, Goetze, JP, Persson, F & Rossing, P 2015, 'Glucagon-like peptide 1 receptor agonist (GLP-1 RA): Long-term effect on kidney function in patients with type 2 diabetes', Journal of Diabetes and its Complications, vol. 29, no. 5, pp. 670-674. https://doi.org/10.1016/j.jdiacomp.2015.04.004

APA

Von Scholten, B. J., Hansen, T. W., Goetze, J. P., Persson, F., & Rossing, P. (2015). Glucagon-like peptide 1 receptor agonist (GLP-1 RA): Long-term effect on kidney function in patients with type 2 diabetes. Journal of Diabetes and its Complications, 29(5), 670-674. https://doi.org/10.1016/j.jdiacomp.2015.04.004

Vancouver

Von Scholten BJ, Hansen TW, Goetze JP, Persson F, Rossing P. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): Long-term effect on kidney function in patients with type 2 diabetes. Journal of Diabetes and its Complications. 2015 Jul 1;29(5):670-674. https://doi.org/10.1016/j.jdiacomp.2015.04.004

Author

Von Scholten, Bernt Johan ; Hansen, Tine Willum ; Goetze, Jens Peter ; Persson, Frederik ; Rossing, Peter. / Glucagon-like peptide 1 receptor agonist (GLP-1 RA) : Long-term effect on kidney function in patients with type 2 diabetes. In: Journal of Diabetes and its Complications. 2015 ; Vol. 29, No. 5. pp. 670-674.

Bibtex

@article{2f8b38a604b44bbbb6028ea41afd4204,
title = "Glucagon-like peptide 1 receptor agonist (GLP-1 RA): Long-term effect on kidney function in patients with type 2 diabetes",
abstract = "Aims In a short-term study including 31 patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment was associated with a significant reversible decline in GFR. Twenty-three patients re-initiated GLP-1 RA treatment after the primary study, and the aim was to investigate the long-term effect on kidney function. Methods We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks. During follow-up 23 were treated with liraglutide and seven untreated. Primary outcome was change in GFR (51Cr-EDTA plasma clearance). Results Patients were 61.5 (10.0) years and HbA1c 60.1 (13.8) mmol/mol. Baseline GFR was 100.6 (24.9) mL/min/1.73 m2 and was reduced by 11 (95% CI: 6.6-15.7, p < 0.001) mL/min/1.73 m2, independent of change in 24-h systolic blood pressure (SBP), weight, UAER or HbA1c (p ≥ 0.33). Geometric mean (IQR) of UAER was 25.5 (9.9-50.9) mg/d and was reduced by 27 (95% CI: 5-44; p = 0.020)%, and 24-h SBP was reduced by 8.2 (p = 0.048) mmHg. No changes occurred in untreated patients. Conclusions Long-term treatment with liraglutide was associated with a reduction in measured GFR similar to the effect during short-term treatment, suggesting a metabolic or haemodynamic reversible effect and not structural changes. Moreover, UAER and 24-h SBP were reduced. Trial registration ClinicalTrials.gov identifier: NCT01499108.",
keywords = "Glomerular filtration rate, GLP-1, Kidney function, Liraglutide, MR-proANP, Urinary albumin excretion rate",
author = "{Von Scholten}, {Bernt Johan} and Hansen, {Tine Willum} and Goetze, {Jens Peter} and Frederik Persson and Peter Rossing",
year = "2015",
month = jul,
day = "1",
doi = "10.1016/j.jdiacomp.2015.04.004",
language = "English",
volume = "29",
pages = "670--674",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide 1 receptor agonist (GLP-1 RA)

T2 - Long-term effect on kidney function in patients with type 2 diabetes

AU - Von Scholten, Bernt Johan

AU - Hansen, Tine Willum

AU - Goetze, Jens Peter

AU - Persson, Frederik

AU - Rossing, Peter

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Aims In a short-term study including 31 patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment was associated with a significant reversible decline in GFR. Twenty-three patients re-initiated GLP-1 RA treatment after the primary study, and the aim was to investigate the long-term effect on kidney function. Methods We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks. During follow-up 23 were treated with liraglutide and seven untreated. Primary outcome was change in GFR (51Cr-EDTA plasma clearance). Results Patients were 61.5 (10.0) years and HbA1c 60.1 (13.8) mmol/mol. Baseline GFR was 100.6 (24.9) mL/min/1.73 m2 and was reduced by 11 (95% CI: 6.6-15.7, p < 0.001) mL/min/1.73 m2, independent of change in 24-h systolic blood pressure (SBP), weight, UAER or HbA1c (p ≥ 0.33). Geometric mean (IQR) of UAER was 25.5 (9.9-50.9) mg/d and was reduced by 27 (95% CI: 5-44; p = 0.020)%, and 24-h SBP was reduced by 8.2 (p = 0.048) mmHg. No changes occurred in untreated patients. Conclusions Long-term treatment with liraglutide was associated with a reduction in measured GFR similar to the effect during short-term treatment, suggesting a metabolic or haemodynamic reversible effect and not structural changes. Moreover, UAER and 24-h SBP were reduced. Trial registration ClinicalTrials.gov identifier: NCT01499108.

AB - Aims In a short-term study including 31 patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment was associated with a significant reversible decline in GFR. Twenty-three patients re-initiated GLP-1 RA treatment after the primary study, and the aim was to investigate the long-term effect on kidney function. Methods We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks. During follow-up 23 were treated with liraglutide and seven untreated. Primary outcome was change in GFR (51Cr-EDTA plasma clearance). Results Patients were 61.5 (10.0) years and HbA1c 60.1 (13.8) mmol/mol. Baseline GFR was 100.6 (24.9) mL/min/1.73 m2 and was reduced by 11 (95% CI: 6.6-15.7, p < 0.001) mL/min/1.73 m2, independent of change in 24-h systolic blood pressure (SBP), weight, UAER or HbA1c (p ≥ 0.33). Geometric mean (IQR) of UAER was 25.5 (9.9-50.9) mg/d and was reduced by 27 (95% CI: 5-44; p = 0.020)%, and 24-h SBP was reduced by 8.2 (p = 0.048) mmHg. No changes occurred in untreated patients. Conclusions Long-term treatment with liraglutide was associated with a reduction in measured GFR similar to the effect during short-term treatment, suggesting a metabolic or haemodynamic reversible effect and not structural changes. Moreover, UAER and 24-h SBP were reduced. Trial registration ClinicalTrials.gov identifier: NCT01499108.

KW - Glomerular filtration rate

KW - GLP-1

KW - Kidney function

KW - Liraglutide

KW - MR-proANP

KW - Urinary albumin excretion rate

UR - http://www.scopus.com/inward/record.url?scp=84930572421&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2015.04.004

DO - 10.1016/j.jdiacomp.2015.04.004

M3 - Journal article

C2 - 25935863

AN - SCOPUS:84930572421

VL - 29

SP - 670

EP - 674

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 5

ER -

ID: 257058522